Applied Therapeutics, Inc.
APLT
$0.10
-$0.01-7.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 573.93% | 136.64% | 155.77% | -95.44% | -101.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 573.93% | 136.64% | 155.77% | -95.44% | -101.98% |
| Cost of Revenue | -25.40% | -8.33% | -11.60% | -9.58% | -44.45% |
| Gross Profit | 27.60% | 9.21% | 12.96% | -9.96% | 37.11% |
| SG&A Expenses | 54.97% | 128.71% | 168.10% | 171.58% | 76.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.27% | 43.51% | 46.71% | 40.55% | 25.85% |
| Operating Income | -7.94% | -42.74% | -45.42% | -61.61% | -47.65% |
| Income Before Tax | 90.32% | 57.95% | 77.52% | 11.81% | -94.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 90.32% | 57.95% | 77.52% | 11.81% | -94.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.32% | 57.95% | 77.52% | 11.81% | -94.08% |
| EBIT | -7.94% | -42.74% | -45.42% | -61.61% | -47.65% |
| EBITDA | -7.94% | -42.74% | -45.42% | -61.61% | -47.66% |
| EPS Basic | 91.57% | 67.88% | 83.74% | 39.79% | -11.87% |
| Normalized Basic EPS | 91.04% | 67.90% | 83.77% | 39.81% | -11.82% |
| EPS Diluted | 91.99% | 70.51% | 75.47% | 28.55% | -23.33% |
| Normalized Diluted EPS | 91.04% | 67.93% | 83.70% | 39.73% | -11.90% |
| Average Basic Shares Outstanding | 10.64% | 23.01% | 42.40% | 65.79% | 89.89% |
| Average Diluted Shares Outstanding | 8.88% | 20.83% | 44.49% | 68.31% | 92.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |